MedTech Dive June 12, 2024
Kardium will use the funding to complete a clinical study for pursuing regulatory approvals and build its manufacturing, clinical support and commercial teams.
Dive Brief:
- Kardium, the developer of a pulsed field ablation and mapping system to treat atrial fibrillation (AFib), said Tuesday it has raised $104 million in a new financing round to help the company prepare for commercial launch.
- The funds will be used to complete Kardium’s Pulsar clinical study needed to obtain regulatory approvals for its Globe mapping and ablation system. The company also plans to expand its manufacturing team and capacity and build a clinical support and commercial team.
- Existing investors Fidelity Management and Research and T. Rowe Price and new investor Durable Capital Partners...
Today's Sponsors
Today's Sponsor